|Bid||1,527.60 x 0|
|Ask||1,527.20 x 0|
|Day's range||1,518.60 - 1,544.20|
|52-week range||1,283.20 - 1,609.00|
|Beta (5Y monthly)||0.30|
|PE ratio (TTM)||12.03|
|Earnings date||01 Nov 2023|
|Forward dividend & yield||0.56 (3.63%)|
|Ex-dividend date||17 Aug 2023|
|1y target est||N/A|
GSK shares have had a good 12 months, easily beating the FTSE 100 index with an 18% gain. So was selling our stock in 2021/22 the wrong move? The post Was selling our GSK shares a big mistake? appeared first on The Motley Fool UK.
I'm looking for shares that will lead the next stock market rally and recent performance suggests these three should all do well. The post Three red hot LSE shares I’d consider buying before the next stock market rally appeared first on The Motley Fool UK.
Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.